跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DOVATO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
DOVATO
Authorized
STANDARD
DOVATO
viiv healthcare ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
fc47be17e6e3dfa9
Company
viiv healthcare ulc
Type
Standard
Approval Details
Approval Id
fc47be17e6e3dfa9
Drug Approval Canada Name
DOVATO
Product Name
DOVATO
Status
Marketed
Status Date
2019-09-09
Original Market Date
2019-09-09
Din
02491753
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.12
Atc Original
J05AR25 LAMIVUDINE AND DOLUTEGRAVIR
Atc Name
j 05 ar 25
Aig Number
0261731001
Company Name
viiv healthcare ulc
Company Address
1400, 75 Rue Queen, Montreal, Quebec, Canada, H3C 2N6
Active Ingredients
LAMIVUDINE
300 MG
DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
50 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
fc47be17e6e3dfa9
Type
Standard
Back to Health Canada Approvals